Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Anne-Marie Daull(Hospices Civils de Lyon), Vincent Alcazer(Lyon 1 Université), Marie Balsat(Hôpital Claude Huriez), Valérie Dubois(Établissement Français du Sang), Fiorenza Barraco(Hôpital Lyon Sud), Florence Ader(Université Claude Bernard Lyon 1), Marie‐Virginie Larcher, Hervé Ghesquières(Université Claude Bernard Lyon 1), Gaëlle Fossard(Hospices Civils de Lyon), Fabienne Venet(Université Claude Bernard Lyon 1), Hélène Labussière‐Wallet(Hospices Civils de Lyon), Maël Heiblig(Université Claude Bernard Lyon 1), Sophie Ducastelle-Leprêtre(Hospices Civils de Lyon), Lila Gilis(Hospices Civils de Lyon)
Cited by 25
Related Papers
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
|The Lancet|2022|407
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309